

Author Index Volume 17 (2005)

The issue number is given in front of the page numbers.

- Akpalu, Jr., A.K., P.K. Nyame and A.N.O. Dodoo, Amodiaquine-induced dystonic reactions: Case reports and implications for policy change in Ghana (1,2) 1– 4
Allotey, N.K., see Dodoo, A.N.O. (1,2) 13– 18
Amofa, G., see Dodoo, A.N.O. (1,2) 13– 18
Andersson, D., The ways in which bacteria resist antibiotics (3,4) 111–116
- Bart-Plange, C., see Dodoo, A.N.O. (1,2) 13– 18
Bhatia, A., U. Kapoor and G. Tayal, A survey of issues regarding ADR and ADR reporting amongst doctors in Delhi (1,2) 39– 46
Briant, R., see Hider, P. (1,2) 81– 89
- Cars, O. and P. Nordberg, Antibiotic resistance – The faceless threat (3,4) 103–110
Cuperus-Bosma, J.M., see de Bie, J. (1,2) 47– 56
- Davis, P., see Hider, P. (1,2) 81– 89
de Bie, J., J.M. Cuperus-Bosma, S.K. Stortenbecker, J.K.M. Gevers and G. van der Wal, Risky procedures: Experiences and views of psychiatrists and views of management of mental health care institutions (1,2) 47– 56
Dodoo, A.N.O., Lapdap[®] – A threat or an opportunity? (3,4) 173–173
Dodoo, A.N.O., M. Gyansa-Lutterodt, N. Frempong, H. Thompson, G. Amofa, C. Bart-Plange, N.K. Allotey and K.E. Eghan, Preliminary safety assessment of sulphadoxine-pyrimethamine during intermittent presumptive treatment of pregnant women in a region with high prevalence of G6PD deficiency (1,2) 13– 18
Dodoo, A.N.O., see Akpalu, Jr., A.K. (1,2) 1– 4
Dukes, M.N.G., Antibiotic use and public policy (3,4) 127–131
Dushoff, J., see Smith, D.L. (3,4) 147–155
- Edwards, I.R., see van Boxtel, C.J. (3,4) 169–172
Eghan, K.E., see Dodoo, A.N.O. (1,2) 13– 18
- Fauci, A.S., N.A. Touchette and G.K. Folkers, Emerging infectious diseases: A 10-year perspective from the National Institute of Allergy and Infectious Diseases (3,4) 157–167
Fluit, A.C., see Verhoef, J. (3,4) 97–102
Folkers, G.K., see Fauci, A.S. (3,4) 157–167
Frempong, N., see Dodoo, A.N.O. (1,2) 13– 18
- Gevers, J.K.M., see de Bie, J. (1,2) 47– 56
Gyansa-Lutterodt, M., see Dodoo, A.N.O. (1,2) 13– 18
- Herxheimer, A., Communicating with patients about harms and risks (1,2) 23– 26

- Hider, P., R. Lay-Yee, P. Davis, R. Briant and A. Scott, Monitoring the quality of primary care: Use of hospital-based audit studies (1,2) 81– 89
- Jansen, W.T.M., see Verhoef, J. (3,4) 97–102
- Kapoor, U., see Bhatia, A. (1,2) 39– 46
- Lay-Yee, R., see Hider, P. (1,2) 81– 89
- Lekkerkerker, J.F.F., see Lisman, J.A. (1,2) 73– 79
- Lisman, J.A. and J.F.F. Lekkerkerker, Four decades of European medicines regulation: What have they brought us? (1,2) 73– 79
- Monnet, D.L., Antibiotic development and the changing role of the pharmaceutical industry (3,4) 133–145
- Morris, Jr., J.G., see Smith, D.L. (3,4) 147–155
- Nordberg, P., C. Stålsby-Lundborg and G. Tomson, Consumers and providers – Could they make better use of antibiotics? (3,4) 117–125
- Nordberg, P., see Cars, O. (3,4) 103–110
- Nyame, P.K., see Akpalu, Jr., A.K. (1,2) 1– 4
- Offerhaus, L., The pharmaceutical industry in discredit: Mercury or Aesculapius? (1,2) 19– 22
- Saunders, A., see Vincent, C. (1,2) 5– 11
- Scott, A., see Hider, P. (1,2) 81– 89
- Smith, A.J., Unfinished business: Clinical Pharmacology and World Health (1,2) 65– 71
- Smith, D.L., J. Dushoff and J.G. Morris, Jr., Agricultural antibiotics and human health: Does antibiotic use in agriculture have a greater impact than hospital use? (3,4) 147–155
- Stålsby-Lundborg, C., see Nordberg, P. (3,4) 117–125
- Stortenbeeker, S.K., see de Bie, J. (1,2) 47– 56
- Suryawati, S., Contribution of clinical pharmacology to improve the use of medicines in developing countries (1,2) 57– 64
- Tayal, G., see Bhatia, A. (1,2) 39– 46
- Thompson, H., see Dodoo, A.N.O. (1,2) 13– 18
- Tomson, G., see Nordberg, P. (3,4) 117–125
- Touchette, N.A., see Fauci, A.S. (3,4) 157–167
- van Boxtel, C.J. and I.R. Edwards, LapdapTM and the Sunday Times – Britain (3,4) 169–172
- van der Bruggen, J.T., see Verhoef, J. (3,4) 97–102
- van der Wal, G., see de Bie, J. (1,2) 47– 56
- Verhoef, J., A.C. Fluit, W.T.M. Jansen and J.T. van der Bruggen, Resistance: A sensitive issue. Strategic Council on Resistance in Europe (3,4) 97–102
- Vincent, C. and A. Saunders, Managing the aftermath of iatrogenic injury (1,2) 5– 11
- Wijnberg, B., Priority medicines for the citizens of Europe and the world: A research and development agenda (1,2) 27– 37